Abstract
Exercise-induced bronchospasm (EIB) is a common, often unrecognized and undiagnosed, condition in children. The goal of treatment for EIB is to allow children and adolescents to maintain activity levels similar to those of their peers. Patients who develop symptoms only after strenuous activity can be treated prophylactically and do not require continuous treatment. Whereas short-acting β2-adrenergic receptor agonists (SABAs; e.g., albuterol) can protect against the symptoms of EIB in 80-95% of cases, these agents may not always be a practical treatment option. Results from small, randomized, placebo-controlled, single-dose studies comparing long-acting β2-adrenergic receptor agonists (LABAs) with SABAs in children and/or young adults have demonstrated that occasional dosing with formoterol or salmeterol provides significantly greater protection against EIB for a longer time than do SABAs. The onset of action of formoterol is comparable to that of albuterol (3 minutes), whereas the onset of action of salm...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
